





# Rubella in pregnancy

- Maryam Afrakhteh.MD
- Shahid Beheshti Medical University
- 2019 Shiraz Iran



# Rubella in pregnancy

- a member of the togavirus family,
- genus Rubivirus, **humans** are the only reservoir for rubella infection.
- Transmitted by direct droplet contact from nasopharyngeal secretions, replicates in the lymph tissue of the **upper respiratory tract**, spreads **hematogenously**.
- Congenital infection occurs when **maternal viremia** allows hematogenous spread of the virus across **the placenta**.



# Congenital rubella syndrome

Congenital rubella syndrome (CRS) refers to variable constellations of birth defects

hearing impairment,

congenital heart defects,

cataracts

congenital glaucoma

pigmentary retinopathy



# congenital rubella syndrome (CRS)

- congenital rubella syndrome (CRS) have largely been eliminated in the **United States**.
- incidence of rubella has declined from
- 0.45 per 100,000 in 1990 to 0.1 per 100,000 in 1999
- rubella outbreaks continue to occur in other parts of the world, and CRS remains a concern.



- rubella vaccine in 1969
- epidemics of rubella occurred in **six to nine** year cycles, usually in the late **winter** and early **spring**.
- rubella susceptible women of childbearing age varies
- 15 percent of women between the ages of 20 and 29 lack antibodies to rubella in **Turkey**
- 23 percent in Nigeria lack antibodies **Russian** Federation, 16.5 percent
-



# Rubella

## CRS

- Even in countries where rubella vaccination programs are available, the extent of vaccination **is not always optimal**
- **Unvaccinated susceptibles** can be a source of many preventable cases of **CRS**



# CLINICAL MANIFESTATIONS

## Rubella

- Acquired rubella is generally a **mild, self-limited** disease associated with a characteristic exanthem
- Symptoms appear approximately **14 to 21 days after inoculation** with the virus.
- Though **asymptomatic in 25 to 50** percent of cases, affected individuals may experience mild, prodromal symptoms consisting of low-grade fever, conjunctivitis, coryza, sore throat, cough,
- headache ; malaise.
- These symptoms usually last **one to five days** before the onset of **the rash**.





# CLINICAL MANIFESTATIONS

## Rubella

- Rubella may also be associated with generalized, tender **lymphadenopathy**, particularly involving **suboccipital**, postauricular, and cervical nodes, which often becomes pronounced during the rash.
- Just prior to the onset of the rash, approximately 20 percent of those infected will develop discrete **rose spots on the soft palat**
- (**Forchheimer spots**) that may later expand and coalesce.
- Polyarthrititis and polyarthralgia are potential sequelae.



# Congenital rubella syndrome

- catastrophic effects on the developing fetus,
- spontaneous abortion,
- fetal infection,
- stillbirth,
- or intrauterine growth restriction



# Congenital rubella syndrome

- Maternal-fetal transmission occurs via **hematogenous spread** and varies with **gestational age**.
- There is considerable pathologic evidence that suggests that the rubella virus spreads through the **vascular system** of the developing fetus after infecting the placenta.
- The resulting defects stem from **cytopathic damage to blood vessels** and ischemia in affected organs



# Congenital rubella syndrome

- first trimester, fetal infection rates **81** percent
- **25** percent in the late second trimester
- third trimester from **35** percent at 27 to 30 weeks
- **100** percent for fetuses exposed beyond **36** weeks
- , the risk of congenital defects after maternal infection is essentially limited to maternal infection in **the first 16 weeks** of pregnancy



# Congenital rubella syndrome

- **infection after 20 weeks'** gestation, intrauterine growth retardation may be the only sequelae of third trimester infection
- no evidence that rubella infection **immediately prior to pregnancy** increases the risk of congenital infection



# DIAGNOSIS

## Acute rubella syndrome

- Most laboratories use **ELISA** due to its convenience, sensitivity, and accuracy.
- ●A **fourfold rise in IgG** titer between acute and convalescent serum specimens
- ●The presence of **rubella specific IgM**
- ●A positive **rubella culture**



# Congenital rubella syndrome

- Serum should be obtained within **7 to 10 days** after the onset of **the rash**
- and repeated **two to three weeks later.**  
Rubella virus may be isolated from
- nasal, blood, throat, urine, or cerebrospinal fluid (CSF) specimens
- . The virus is generally isolated from the **pharynx one week before to two weeks after the rash.**



# Congenital rubella syndrome

- . In persons with no or low risk of exposure to rubella, the **reactive IgM** is likely falsely positive due to **rheumatoid factor**
- or **other antibodies** to infection which can **cross react** with the assay.
- Use of rubella specific avidity assay may be useful in these situations.





# Prenatal diagnosis

- Polymerase chain reaction (**PCR**) is another option for providing presumptive diagnosis of rubella infection.
- A reverse transcription-nested **PCR** assay has been used in small studies where it detects rubella virus in **chorionic villous samples (CVS) and amniotic fluid** samples of affected pregnancies.



# Prenatal diagnosis

- rubella specific **PCR on CVS** samples may be superior to standard serologic testing on **fetal blood**.
- **CVS sampling** ideally done at **10 to 12 weeks'** gestation would allow for earlier detection than other samples, such as **fetal blood obtained at 18 to 20 weeks'** gestation



# Prenatal diagnosis

- **Ultrasound diagnosis** of an affected fetus would be extremely difficult given the nature of the malformations seen with **CRS**,
- although, the workup of any fetus with intrauterine growth restriction should include evaluation for congenital viral infections including rubella.



# TREATMENT

- Treatment for acute rubella infection may include [acetaminophen](#) for symptomatic relief. Glucocorticoids, platelet transfusion



# Prenatal diagnosis

- because of the potentially devastating effects on the fetus, women should be counseled about **maternal-fetal transmission** and offered **pregnancy termination**, especially prior to 16 weeks' gestation.
- After 20 weeks' gestation, management should be individualized, and parents should be counseled about the potential for delayed consequences of rubella infection



- There is no definitively beneficial in **utero treatment** available for exposed or affected fetuses.
- The use of [immune globulin](#) for pregnant women with acute infection is **controversial**.
- There are no data to suggest that IgG has a beneficial effect on the fetal response to disease.
- Thus, the Centers for Disease Control and Prevention (CDC) **recommends limiting** the use of immune globulin to women with known rubella exposure who decline pregnancy termination



# PREVENTION

- **single dose of this vaccine** given at one year of age or older results in measurable antibody in almost 95 percent of susceptible persons
- Vaccination is recommended for all children at 12 to 15 months and 4 to 6 years in conjunction with measles and mumps (**MMR**).
- All other persons should be vaccinated unless immunity is documented by serology.



# Postpartum vaccination programs

- Postpartum vaccination programs have been shown to significantly reduce rubella susceptibility in pregnant **seronegative women**
- Rubella vaccine virus may cross the placenta and infect the fetus.
- However, there have been **no cases of CRS** reported in women inadvertently vaccinated during early pregnancy
- pregnancy termination is **not** recommended for these women







# Rubella in Neonate

Dr. Mehrdad Rezaei  
Neonatologist - SUMS



# RUBELLA (CONGENITAL)

- This human-specific RNA virus is a member of the Togavirus family. It causes a mild self-limiting infection in susceptible children and adults, but **its effects on the fetus can be devastating.**






# Rubella Fetal infection & damage:

- Rate of fetal infection

first 12 weeks of gestation	81%.
13 to 16 weeks of gestatio	54%,
17 to 22 weeks of gestation	36%,
23 to 30 weeks of gestation	30%
31 to 36 weeks of gestation	60%
>=36 weeks of gestation	100%



Early gestation infection may result in multiple organ anomalies.

- Rate of fetal damage

infected before <b>8</b> weeks' gestation	52%,
infected at <b>9 to 12</b> weeks' gestation	36%,
infected at 13 to 20 weeks' gestation	10%
infection <b>beyond 20 weeks'</b> gestation	<b>0%</b>



# Clinical manifestations:

## Congenital rubella Syndrome (CRS is not a static disease)

- **75%** infected infants show **no apparent involvement at birth**, but develop consequences years later.
- Classically, CRS is characterized by **cataracts, SNHL, cong. heart dis.**
- **IUGR** (birth weight is often <1500 g) ( continue to FTT postnatally).
- These infants often have **myriad transient symptoms**, including **thrombocytopenia, petechiae, purpura, hemolytic anemia, hepatitis, jaundice, HSM, “blueberry muffin” spots** (50%)
- **myocarditis, cloudy cornea, long bone radiolucencies, interstitial pneumonia, and meningoencephalitis**, manifested by an elevated CSF protein level and pleocytosis



- sensorineural deafness (75%), usually **bilateral**. Deafness may be the only sequela of congenital infection and may occur with maternal infection **up to 20 weeks' gestation**.
- Congenital heart disease occurs only when the fetus is infected during the **first 8 weeks** of gestation.  
**PDA**, the most common lesion, may occur alone or in conjunction with **pulmonary artery or valvular stenosis**, or there may be stenoses of other vessels.



- **Microcephaly and neuropsychiatric problems**

26% of children were severely **mentally retarded**, 12% had neurologic problems, 18% had **behavioral** abnormalities, and 6% had **autism**.

- **Ophthalmologic abnormalities** : **cataracts** (30%), often bilateral and occasionally accompanied by **glaucoma**. Other children may have **microphthalmos** or characteristic **salt-and-pepper chorioretinitis**. Rubella RNA can be detected and quantified in the **lens** of affected infants.



A 20-year follow-up study:

- **ocular disease** (most common disorder 78%),
- **sensorineural hearing deficits** (66%),
- psychomotor retardation (62%),
- cardiac abnormalities (58%),
- mental retardation (42%).





- Immune globulin is **not recommended** for prophylaxis in an exposed pregnant woman because congenital rubella has occurred despite the lack of symptoms in women given immune globulin.
- vaccination after exposure does **not prevent** infection from the current exposure, but might prevent exposure and infection in the future.
- The goal is to eliminate rubella with **vaccination**. Infants should be vaccinated at 12 to 15 months of age and again at school entry



- children with CRS: **contagious for at least 1 year**, unless repeated urine and blood cultures are negative.
- **Pregnancy women should not be vaccinated** because **3%** of fetuses may be subclinically infected, but birth defects have **not** been reported after vaccination of pregnant women, even if the fetus is infected.
- It is **acceptable to vaccinate children of pregnant women** because there is no evidence of transmission of virus after vaccination.



# **Congenital Rubella syndrome : Lab diagnosis in neonates**

Dr Gholamreza Pouladfar



# Evaluation

- The evaluation of a newborn with clinical findings compatible with intrauterine rubella infection (eg, **cataract, congenital cardiac defect**) is the same as the evaluation for other intrauterine infections.



# Evaluation

- 1) Review of maternal history (evidence of rubella immunity)
- 2) Assessment of physical stigmata consistent with the syndrome, including complete cardiac and neurologic examinations
- 3) CBC & Platelet
- 4) LFT
- 5) Radiographs of long bones
- 6) Ophthalmologic evaluation
- 7) Audiologic evaluation
- 8) Neuroimaging (eg, ultrasonography, CT)
- 9) LP
- 10) Echocardiography: **?:** all vs +P/E



# Time of evaluation

- Laboratory evaluation should be performed **before** the child reaches **one year of age**,  
after which  
it is **difficult to establish** a diagnosis of CRI



# Laboratory confirmation of CRI

- 1) Isolation of rubella virus
- 2) Demonstration of rubella-specific IgM Ab
- 3) Demonstration of rubella-specific IgG Abs
  - Persist at a higher concentration or longer duration than expected from passive transfer of maternal antibody
- 4) Detection of rubella virus RNA



# Virus isolation

- Confirmation of CRI
- The most frequently isolated site
  - **Nasopharyngeal secretions**
- Other sites:
  - 1) Blood (including cord blood)
  - 2) Placenta
  - 3) Urine
  - 4) CSF





# Virus isolation

- Special tests:
  - Laboratory personnel should be notified that rubella virus is suspected.
- Timing:
  - As soon as CRI is suspected
  - Viral excretion wanes during infancy
  - for several years
    - Isolation of rubella virus may be possible from lens tissue in children with cataracts or CSF in children with encephalitis



## Serologic confirmation of CRS: Developing countries

- Demonstration of rubella-specific IgM Abs:
  - With commercially available enzyme immunoassay kits
  - **the preferred initial test**
  - particularly for infants in the first **2 months** of life
  - may be detectable for as long as **12 months** in some infants
  - Infants with symptoms consistent with CRS who test **negative soon after birth** should be **retested at age one month**
    - Approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month
    - In infants older than two months, positive IgM is helpful, but negative IgM does not exclude infection.
    - False-positive IgM
    - RF, parvovirus, and heterophile antibodies



## Serologic confirmation of CRS: Developing countries

- **OR**
- Rubella-specific IgG
  - Most helpful in infants between 6 and 12 months of age
  - for a longer time than expected from passive transfer of maternal antibody
  - Monitoring rubella-specific IgG over time (eg, at **3, 6,** and, if necessary, **12** mo of age)
  - Maternal rubella antibody has a half-life of approximately 30 days
  - Decrease by **4 to 8 fold** by **three months of age**
  - Disappear by **6 to 12 mo** of age



# Rubella virus polymerase chain reaction

- Detection of rubella virus RNA by polymerase chain reaction (PCR)
- May not be available in all settings
- Samples:
  - 1) throat swabs
  - 2) Respiratory secretions
  - 3) Central nervous system tissues and CSF
  - 4) Amniotic fluid
  - 5) Products of conception
  - 6) Urine samples
  - 7) Lens tissue (in children with ocular anomalies)



# Viral shedding

- After fetal infection, rubella virus persists throughout gestation and for months postnatally. It can be **recovered from multiple sites.**
- Pharyngeal shedding
  - Common
  - Prolonged
    - At one year of age, as many as 20%
    - By two years of age: rare
  - Intense during the months after delivery.



# Viral shedding

- Ocular involvement (eg, cataracts)
  - Cultured from the crystalline lens in children older than one year of age
- CNS (eg. late subacute panencephalitis)
  - Cultured from cerebrospinal fluid in children older than one year of age



# Retrospective diagnosis

- It is difficult to establish a diagnosis of CRI in children older than one year of age
  - 1) Detection of persistent rubella RNA by PCR.
  - 2) Measuring lymphocyte response to rubella in vitro
  - 3) Measuring rubella IgG avidity (strength of antigen-antibody binding); children with intrauterine rubella infection have low rubella-specific IgG avidity
  - 4) Measuring antibody response to rubella vaccination (in children with compatible manifestations but nondetectable antibody); children with CRS generally do not respond to rubella vaccination